Evidence map›Paper›PMID 39887289›Full record

ArticleFuture medicinal chemistry2025

Dual delivery of metformin and Y15 from a PLGA scaffold for the treatment of platinum-resistant ovarian cancer.

Emily Jordan, Marco A Arriaga, Hannah Obregon, Viviana Villalobos, Manuel A Duarte, Kristal Garcia, Arkene Levy, Sue Anne Chew

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. How PLGA Microspheres are Emerging as a Key Drug Delivery System.International journal of nanomedicine · 2026
    Review
  2. Nanocarrier drug delivery systems for gynecological cancer therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Emily JordanDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, TX, USA.
Marco A ArriagaDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, TX, USA.
Hannah ObregonDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, TX, USA.
Viviana VillalobosDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, TX, USA.
Manuel A DuarteDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, TX, USA.
Kristal GarciaDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, TX, USA.
Arkene LevyDr Kiran C Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA.
Sue Anne ChewDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, TX, USA.ORCID 0000-0003-0153-6213

Funding

Bridges to the Baccalaureate Research Training Program at The University of Texas Rio Grande ValleyT34GM137854 · NIGMS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHEW, SUE ANNE, GALVEZ, GRISELDA LOPEZ · 2020 to 2024
$1.9M
Local dual delivery of a chemotherapy and an anti-angiogenic agent from an injectable functionalized biodegradable biomaterial system for the treatment of gliomasSC3GM135138 · NIGMS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHEW, SUE ANNE · 2020 to 2023
$436k
NIGMS NIH HHS SC3 GM135138NIGMS NIH HHS T34 GM137854
6 · The paper itself

Abstract

aimsDrug-loaded poly(lactic-co-glycolic acid) (PLGA) scaffolds were fabricated using a mold-less technique to investigate whether the combined delivery of both Y15 (FAK inhibitor) and metformin would result in enhanced effects on cell viability compared to the release of each drug alone for the treatment of platinum-resistant ovarian cancer (PROC). MATERIALS &

methodsScaffolds were fabricated using an easy and economical mold-less technique that combined PLGA and the drugs (i.e. metformin and/or Y15) in tetraglycol and injected in PBS, to form a globular morphology.

resultsThe exposure of cells to metformin and Y15 resulted in a significantly enhanced cytotoxic efficacy compared to single-drug treatment with either metformin or Y15. When the drugs were delivered using the PLGA scaffolds, the combination of the two drugs was significantly more cytotoxic compared to scaffolds containing metformin only and Y15 only.

conclusionsThe combination of metformin and Y15 can result in an increase in antitumor activity in PROC cells through apoptosis. The delivery of both drugs from the PLGA biomaterial scaffold allowed for a more enhanced combinational effect compared to the utilization of free drugs (without a scaffold) and should be further explored as a promising treatment of PROC.

Indexed as

Antineoplastic AgentsDrug CarriersDrug Resistance, NeoplasmMetforminOvarian NeoplasmsPolylactic Acid-Polyglycolic Acid CopolymerApoptosisCell Line, TumorCell ProliferationCell SurvivalDrug Screening Assays, AntitumorFemaleHumansPlatinumAntineoplastic AgentsDrug CarriersMetforminPlatinumPolylactic Acid-Polyglycolic Acid Copolymerbiomaterialscytotoxicityfocal adhesion kinaseMetforminovarian cancerY15

Identifiers

PMID39887289
PMCPMC11792864

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.